Vivid Dx is an Oxford, UK-based provider of a precision diagnostics platform improving pathogen detection and antimicrobial resistance (AMR) testing.
Vivid Dx has raised €13M across 1 funding round from 4 investors, most recently a Seed round in Jul 2026. Based in Oxford, UK; active in Healthtech. Data as of 29 Jul 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-29 | Seed | €13M |
| Cedars-Sinai Intellectual Property Co.,Jameel Investment Management Company,other investors,Oxford Science Enterprises |
| View deal → |
